1. Rheumatoid Arthritis

3. Introduction

4. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab

5. JAK/STAT Pathway: Communication From Transmembrane Receptors to the Nucleus

6. Currently Available JAK Inhibitors for RA

7. Early vs Delayed Start of Baricitinib in Patients Naive to MTX Treatment

8. MTX Withdrawal in Patients Who Achieve LDA With Tofacitinib MR 11 mg QD + MTX

9. Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to MTX

10. Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to DMARDs

11. FINCH1: Efficacy and Safety of Filgotinib in MTX-IR Patients

12. FINCH3: Efficacy and Safety of Filgotinib in MTX-Naive Patients

13. FINCH2: Subgroup Analyses

14. Switching Between Upadacitinib and ADA Following Initial Non-Response

15. Upadacitinib SELECT Trials: 48-Week Results

16. Fenebrutinib Compared to PBO and ADA in MTX-IR or TNF-IR Patients

17. Safety and Efficacy of LY3337641 in Patients With RA: Phase 2 Study

18. Subcutaneous Administration of Infliximab Biosimilar (CT-P13)

19. Concluding Remarks

20. Abbreviations

21. Abbreviations (cont)